Muscle atrophy signaling pathways have been well-documented [54], and one of the atrogenes (i.e., Fbxo32/MAFbx32/Atrogin-1) was significantly activated by BTX treatment in this study. The gene discussed is FBXO32; the disease is muscle atrophy.